COPENHAGEN, Denmark, Feb. 11 /PRNewswire/ -- Santaris Pharma, the Danish biopharmaceutical company developing LNA based RNA medicines, announced today that Keith McCullagh, President and Chief Executive Officer, will be presenting an overview of the company and its goals for 2008 at the Biotechnology Industry Organisation's 10th Annual CEO & Investor Conference in New York, today, Monday February 11th at 12:30 pm, US Eastern Standard Time (18:30 Central European Time). The conference is being held at the Waldorf Astoria Hotel, New York City from February 11th-13th, 2008.
A live webcast of the Santaris Pharma presentation may be accessed from the news section of the company's website, http://www.santaris.com, where it will also be archived and available after the presentation.
About Santaris Pharma
Santaris Pharma is a Danish based clinical-stage biopharmaceutical
company. The company was formed in 2003 and currently employs around 100
people. Santaris Pharma has the exclusive rights to LNA technology, a 3rd
generation antisense chemistry used to develop new classes of RNA
medicines, called RNA Antagonists and microRNA antagonists. Santaris
Pharma's RNA Antagonists are targeted against tissue specific mRNAs
associated with cancer, metabolic disorders and viral disease. In May 2006
Santaris Pharma completed a Euro 40m second round of equity financing and
in December 2007 the Company completed a Euro 20m third round of equity
financing. Santaris Pharma has a global partnership with Enzon
Pharmaceuticals of New Jersey to co-develop and commercialise a series of
Santaris Pharma RNA Antagonists for improving the treatment of cancer.
GlaxoSmithKline has options to up to four Santaris Pharma drug candidates
targeted against viral disease.
For further information please contact
Randi Krogsgaard, Director Corporate Communications
Direct phone: +45 45179879
|SOURCE Santaris Pharma|
Copyright©2008 PR Newswire.
All rights reserved